Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 53

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 53
---
 condition, prospects,
operating results, cash needs, growth plans, applicable Delaware law, which provides that dividends are only payable out of surplus or
current net profits, and other factors our board might deem relevant. There are no restrictions that currently limit our ability to pay
dividends on our common stock other than those generally imposed by applicable state law.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our consolidated
cash and capitalization as of March 31, 2025:

| ● | On an actual basis; and |

| ● | On an as adjusted basis giving effect to the sale of up to 2,036,659 shares                                                                 
 of common stock, or, in lieu thereof, Pre-Funded Warrants to purchase up to 2,036,659  shares of common stock, and accompanying Series      
 A-1 Warrants to purchase up to 2,036,659 shares of common stock and Series A-2 Warrants to purchase up to 2,036,659 shares of common stock  
 by us in this public offering at an assumed public offering price of $2.455 per share (the last reported sale price of our common stock     
 on The Nasdaq Capital Market on July 2, 2025), after deducting estimated placement agent fees and estimated offering expenses payable       
 by us, and assuming exercise in full of any Pre-Funded Warrants offered in this offering, no exercise of the Series A-1 Warrants and Series 
 A-2 Warrants being offered in this offering and no value being attributed to the Warrants                                                   |

You should read the following table in conjunction
with the section titled “Use of Proceeds” in this prospectus and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as our financial statements and related notes appearing in our Annual
Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2025,
which are incorporated by reference in this prospectus.

The information set forth below is illustrative
only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

|                                                                                                                                                                                                           |     | Actual |             |   |     | As          
 Adjusted(1) |             |   |
|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-------|------------:|:--|:----|:------------|------------